Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ARRB1 | P49407 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL10031250 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8285398 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL15501048 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL6393384 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL12125412 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL12717556 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL5674635 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2421178 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13695381 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022127320-A1 | INTERMEDIATE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 四川大学 | 2022-06-23 | — | — | WO | disclosed |
| EP-3470416-B1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11173209-B2 | Compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021084217-A1 | PRODUCTION PROCESS OF A HYDROCHLORIC ACID SALT OF APOMORPHINE AND DERIVATIVES THEREOF | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2021-05-06 | — | — | WO | disclosed |
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | LABORATORY SKIN CARE, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200138956-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2020-05-07 | — | — | US | disclosed |
| US-10576156-B2 | Compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-08-15 | — | — | US | disclosed |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3470416-A1 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE | Alere San Diego, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-8173666-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110237614-A1 | Pegylated Opioids with Low Potential for Abuse | NEKTAR THERAPEUTICS (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237614-A1 | Pegylated Opioids with Low Potential for Abuse | NEKTAR THERAPEUTICS (US) | 2011-09-29 | — | — | US | disclosed |
| EP-1399161-B1 | SUSTAINED-RELEASE ANALGESIC COMPOUNDS | CONTROL DELIVERY SYSTEMS (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7767428-B2 | Salutaridinol 7-O-acetyltransferase and derivatives thereof | DONALD DANFORTH PLANT SCIENCE CENTER (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| EP-1810973-A1 | 6-monoacetylmorphine derivatives useful in immunoassay | Roche Diagnostics GmbH (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-7238791-B1 | 6-monoacetylmorphine derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070142628-A1 | 6-Monoacetylmorphine derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173209-B2 | Compositions for drug administration | SLC10A1, ABCB11, CSGALNACT1 | OPRM1 2050/4885OPRD1 3158/4885OPRK1 2869/4885 |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20110237614-A1 | Pegylated Opioids with Low Potential for Abuse | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | CHERP, ORAI1, CA2 | OPRM1 4536/4885OPRD1 4265/4885OPRK1 4306/4885 |
| US-20200138956-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC10A1, ABCB11, CSGALNACT1 | OPRM1 2050/4885OPRD1 3158/4885OPRK1 2869/4885 |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20070142628-A1 | 6-Monoacetylmorphine derivatives useful in immunoassay | OPRM1, MAG, IL6ST | OPRM1 1/4885OPRD1 67/4885OPRK1 24/4885 |
| US-10576156-B2 | Compositions for drug administration | SLC10A1, ABCB11, CSGALNACT1 | OPRM1 2050/4885OPRD1 3158/4885OPRK1 2869/4885 |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.